Nxera Pharma Balance Sheet Health
Financial Health criteria checks 3/6
Nxera Pharma has a total shareholder equity of ¥69.0B and total debt of ¥66.3B, which brings its debt-to-equity ratio to 96.1%. Its total assets and total liabilities are ¥156.5B and ¥87.5B respectively.
Key information
96.1%
Debt to equity ratio
JP¥66.27b
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥50.98b |
| Equity | JP¥68.98b |
| Total liabilities | JP¥87.50b |
| Total assets | JP¥156.48b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 4565's short term assets (¥63.6B) exceed its short term liabilities (¥15.5B).
Long Term Liabilities: 4565's short term assets (¥63.6B) do not cover its long term liabilities (¥72.0B).
Debt to Equity History and Analysis
Debt Level: 4565's net debt to equity ratio (22.2%) is considered satisfactory.
Reducing Debt: 4565's debt to equity ratio has increased from 8.1% to 96.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4565 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 4565 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.